| Patient |
Amifostine dose received (%)* |
Neoadjuvant chemotherapy dose received (%) 1stcycle/2ndcycle* |
Disease Status |
|
|
|||
| 1 |
31 |
81/75 |
CR** |
| 2 |
7 |
71/57 |
CR |
| 3 |
16 |
64/11 |
PR*** |
| 4 |
27 |
100/26 |
PR |
| 5 |
73 |
100/100 |
CR |
| 6 |
24 |
52/3 |
CR |
| 7 |
63 |
62**** |
PR |
| 8 |
87 |
86**** |
dead |
| 9 |
7 |
91/28 |
CR |
| 10 |
67 |
72/79 |
CR |
|
*denotes the lowest percentage of administered drug for a cycle ** complete response (CR) ***partial response (PR) ****second cycle not give | |||
Jatoi et al. International Seminars in Surgical Oncology 2004 1:9 doi:10.1186/1477-7800-1-9 |
|||